Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMD670 in ambulatory adults with type 3 spinal muscular atrophy
NL-OMON56350Phase 2Recruiting
- Sponsor
- NMD Pharma
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ignaseclant in spinal muscular atrophy (SMA) and Spinal muscular atrophy type 3 (SMA3), sponsored by NMD Pharma. Primary endpoint: Change from baseline in 6-minute walk test distance after 21-day dosing. Started Sep 2023; status: recruiting.
02
Drugs
ignaseclant
03
Conditions
spinal muscular atrophy (SMA)Spinal muscular atrophy type 3 (SMA3)
Beyond the preview
Go deeper on NL-OMON56350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56350.